Abstract
This is a summary of the original article ‘Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis’. Juvenile idiopathic arthritis (JIA) usually appears before the age of 16. JIA causes pain, swelling, and stiffness in the joints. People with JIA receive treatment for several years until the disease goes into prolonged remission. Therefore, the long-term safety of these treatments is an important topic. Etanercept is a treatment for JIA, which acts on the body’s immune system to reduce arthritis. This summary of research article describes safety and how well etanercept works in children with JIA taking it for up to 10 years.
Avoid common mistakes on your manuscript.
Summary of Research
This is a summary of a peer-reviewed article previously published in the journal Rheumatology: Vojinović J, Foeldvari I, Dehoorne J, et al. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis. Rheumatology (Oxford). 2024;63(1):140–148. [1]. Reproduced by permission of Oxford University Press on behalf of the British Society for Rheumatology (Fig. 1).
Summary of research
Data Availability
Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.
Reference
Vojinović J, Foeldvari I, Dehoorne J, et al. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis. Rheumatology. 2024;63:140–148. https://doi.org/10.1093/rheumatology/kead183
Acknowledgements
For acknowledgements, please see the original publication.
Medical Writing and Editorial Assistance
The first draft of this summary was written by Andrea Schauenburg, PhD, CMPP, of Engage Scientific Solutions under the supervision of the PRINTO officers (NR and AM), and was funded by Pfizer.
Funding
The CLIPPER and CLIPPER2 studies were sponsored by Pfizer. The journal’s Rapid Service Fee for this article was funded by Pfizer.
Author information
Authors and Affiliations
Consortia
Contributions
The trial was designed jointly by PRINTO investigators (NR, AM) and the sponsor. Data were collected by the PRINTO investigators. The sponsor was involved in the overall management of the trial, data collection, and data analysis. All authors reviewed and approved the final document.
Corresponding author
Ethics declarations
Conflict of Interest
Please see the original article for full author disclosures. Edmund Arthur is now an employee of Johnon & Johnson and Bonnie Vlahos is now retired.
Ethical Approval
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Please see the referenced article for ethics relating to the original study.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Vojinović, J., Foeldvari, I., Dehoorne, J. et al. Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis. Rheumatol Ther (2024). https://doi.org/10.1007/s40744-024-00703-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40744-024-00703-z